Profil
Robert Freisen worked as the Head of Preclinical & Early Clinical Development at MorphoSys AG.
He was the Vice President of Preclinical & Clinical Research at Janssen Biotherapeutics from 2008 to 2014.
He served as the Senior VP of Science & Early Development at ProQR Therapeutics NV from 2016 to 2018.
In 2018, he became the Chief Scientific Officer at Ablynx NV.
Dr. Freisen holds a doctorate degree from The University of Texas at Austin and an undergraduate degree from the University of Utrecht.
Anciens postes connus de Robert Freisen
| Sociétés | Poste | Fin |
|---|---|---|
| ABLYNX | Chief Tech/Sci/R&D Officer | 01/01/2019 |
| PROQR THERAPEUTICS N.V. | Corporate Officer/Principal | 01/01/2018 |
| Janssen Biotherapeutics | Corporate Officer/Principal | 01/01/2014 |
| MORPHOSYS AG | Corporate Officer/Principal | - |
Formation de Robert Freisen
| The University of Texas at Austin | Doctorate Degree |
| University of Utrecht | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MORPHOSYS AG | Health Technology |
| PROQR THERAPEUTICS N.V. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
| Janssen Biotherapeutics |
